paliperidone palmitate

Long-acting injectable antipsychotic • Brands: INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA

Last reviewed: 2025-12-30

General information

Class: Long-acting injectable antipsychotic
Common US brands: INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Long-acting injectable prodrug of paliperidone (D2 and 5-HT2A antagonist; active metabolite of risperidone) used for maintenance treatment with monthly, 3-month, or 6-month dosing intervals depending on formulation.

Metabolism & Half‑life

Metabolism: Minimal hepatic metabolism; largely excreted unchanged
Half‑life: Steady-state range 600–1176 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Long‑acting injectable (LAI)

Paliperidone palmitate (PP1M/PP3M/PP6M)

Interval: Monthly / q3mo / q6mo
Oral overlap: None after loading sequence
Site: Deltoid (initiation) or gluteal

Citations

Label Label Label PMCID

Monitoring highlights

Sources

INVEGA SUSTENNA (paliperidone palmitate) prescribing information — DailyMed / Janssen Pharmaceuticals (2025)
INVEGA TRINZA (paliperidone palmitate) prescribing information — DailyMed / Janssen Pharmaceuticals (2025)
INVEGA HAFYERA (paliperidone palmitate) prescribing information — DailyMed / Janssen Pharmaceuticals (2025)
Paliperidone palmitate maintenance treatment in delaying time to relapse in patients with schizophrenia — Schizophrenia Research (2010)